🏢CompaniesPfizer Boosts 2026 Revenue Outlook Amid Ongoing Turnaround Efforts
Pfizer has raised its full-year 2026 revenue guidance by $1.5 billion, signaling stronger-than-expected performance despite persistent challenges in its drug pipeline.
Topic: Revenue
🏢Companies
🏛️EconomyHawkEye 360 Shares Surge 16% on Strong Sales and Positive Cash Flow
HawkEye 360 shares jumped 16% following a strong third-quarter sales report and positive free cash flow, despite posting a net loss.